Trade CureVac N.V. - CVAC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
CureVac NV ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 3.02 |
Open* | 3.07 |
1-Year Change* | -53.83% |
Day's Range* | 3.05 - 3.14 |
52 wk Range | 3.41-12.48 |
Average Volume (10 days) | 1.02M |
Average Volume (3 months) | 21.99M |
Market Cap | 815.08M |
P/E Ratio | -100.00K |
Shares Outstanding | 223.92M |
Revenue | 46.63M |
EPS | -1.51 |
Dividend (Yield %) | N/A |
Beta | 2.60 |
Next Earnings Date | Apr 23, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 3.02 | 0.06 | 2.03% | 2.96 | 3.05 | 2.87 |
Mar 26, 2024 | 2.92 | -0.19 | -6.11% | 3.11 | 3.23 | 2.87 |
Mar 25, 2024 | 3.12 | 0.14 | 4.70% | 2.98 | 3.16 | 2.98 |
Mar 22, 2024 | 3.02 | 0.03 | 1.00% | 2.99 | 3.10 | 2.97 |
Mar 21, 2024 | 3.00 | 0.08 | 2.74% | 2.92 | 3.06 | 2.91 |
Mar 20, 2024 | 3.02 | 0.25 | 9.03% | 2.77 | 3.02 | 2.73 |
Mar 19, 2024 | 2.90 | -0.21 | -6.75% | 3.11 | 3.18 | 2.90 |
Mar 18, 2024 | 3.18 | -0.05 | -1.55% | 3.23 | 3.26 | 3.16 |
Mar 15, 2024 | 3.27 | 0.02 | 0.62% | 3.25 | 3.32 | 3.23 |
Mar 14, 2024 | 3.31 | 0.02 | 0.61% | 3.29 | 3.34 | 3.22 |
Mar 13, 2024 | 3.33 | 0.04 | 1.22% | 3.29 | 3.48 | 3.29 |
Mar 12, 2024 | 3.37 | -0.01 | -0.30% | 3.38 | 3.45 | 3.24 |
Mar 11, 2024 | 3.33 | -0.07 | -2.06% | 3.40 | 3.56 | 3.29 |
Mar 8, 2024 | 3.40 | 0.12 | 3.66% | 3.28 | 3.48 | 3.28 |
Mar 7, 2024 | 3.29 | 0.04 | 1.23% | 3.25 | 3.32 | 3.23 |
Mar 6, 2024 | 3.25 | 0.01 | 0.31% | 3.24 | 3.32 | 3.24 |
Mar 5, 2024 | 3.30 | 0.04 | 1.23% | 3.26 | 3.34 | 3.24 |
Mar 4, 2024 | 3.35 | -0.03 | -0.89% | 3.38 | 3.40 | 3.23 |
Mar 1, 2024 | 3.39 | 0.05 | 1.50% | 3.34 | 3.50 | 3.34 |
Feb 29, 2024 | 3.39 | -0.04 | -1.17% | 3.43 | 3.51 | 3.35 |
CureVac N.V. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, April 23, 2024 | ||
Time (UTC) 06:30 | Country US
| Event Q4 2023 CureVac NV Earnings Release Q4 2023 CureVac NV Earnings ReleaseForecast -Previous - |
Tuesday, May 21, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 CureVac NV Earnings Release Q1 2024 CureVac NV Earnings ReleaseForecast -Previous - |
Tuesday, June 18, 2024 | ||
Time (UTC) 12:00 | Country US
| Event CureVac NV Annual Shareholders Meeting CureVac NV Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 67.42 | 102.99 | 48.871 | 17.416 | 12.871 |
Revenue | 67.42 | 102.99 | 48.871 | 17.416 | 12.871 |
Cost of Revenue, Total | 159.045 | 238.195 | 14.173 | 27.983 | 17.744 |
Gross Profit | -91.625 | -135.205 | 34.698 | -10.567 | -4.873 |
Total Operating Expense | 316.877 | 515.253 | 158.686 | 116.914 | 85.695 |
Selling/General/Admin. Expenses, Total | 95.264 | 93.164 | 48.169 | 48.367 | 24.644 |
Research & Development | 53.9 | 811.648 | 111.23 | 42.768 | 40.579 |
Depreciation / Amortization | 20.346 | 13.24 | 8.696 | 2.831 | 2.873 |
Other Operating Expenses, Total | -36.186 | -574.6 | -23.582 | -5.035 | -0.145 |
Operating Income | -249.457 | -412.263 | -109.815 | -99.498 | -72.824 |
Interest Income (Expense), Net Non-Operating | 0.302 | -0.235 | -20.033 | -0.627 | 1.693 |
Net Income Before Taxes | -249.155 | -412.498 | -129.848 | -100.125 | -71.131 |
Net Income After Taxes | -249.029 | -411.716 | -129.122 | -99.873 | -71.241 |
Net Income Before Extra. Items | -249.029 | -411.716 | -129.122 | -99.873 | -71.241 |
Net Income | -249.029 | -411.716 | -129.122 | -99.873 | -71.241 |
Income Available to Common Excl. Extra. Items | -249.029 | -411.716 | -129.122 | -99.873 | -71.241 |
Income Available to Common Incl. Extra. Items | -249.029 | -411.716 | -129.122 | -99.873 | -71.241 |
Diluted Net Income | -249.029 | -411.716 | -129.122 | -99.873 | -71.241 |
Diluted Weighted Average Shares | 194.997 | 187.121 | 180.461 | 176.46 | 176.46 |
Diluted EPS Excluding Extraordinary Items | -1.27709 | -2.20027 | -0.71551 | -0.56598 | -0.40372 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -1.17342 | -2.35167 | -0.71551 | -0.56598 | -0.40372 |
Unusual Expense (Income) | 24.508 | -66.394 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 7.579 | 7.129 | 11.689 | 11.212 | 20.146 |
Revenue | 7.579 | 7.129 | 11.689 | 11.212 | 20.146 |
Cost of Revenue, Total | 25.855 | 20.634 | 80.001 | 24.079 | 42.681 |
Gross Profit | -18.276 | -13.505 | -68.312 | -12.867 | -22.535 |
Total Operating Expense | 79.381 | 67.484 | 133.199 | 63.592 | 80.445 |
Selling/General/Admin. Expenses, Total | 20.682 | 21.005 | 24.937 | 23.988 | 24.492 |
Research & Development | 29.084 | 22.526 | 22.832 | 10.765 | 10.53 |
Depreciation / Amortization | 4.754 | 4.831 | 6.998 | 5.106 | 4.274 |
Unusual Expense (Income) | -0.413 | -0.31 | -0.063 | -0.273 | -0.035 |
Other Operating Expenses, Total | -0.581 | -1.202 | -1.506 | -0.073 | -1.497 |
Operating Income | -71.802 | -60.355 | -121.51 | -52.38 | -60.299 |
Interest Income (Expense), Net Non-Operating | 4.414 | 2.937 | -7.24 | 4.734 | 2.729 |
Net Income Before Taxes | -67.388 | -57.418 | -128.75 | -47.646 | -57.57 |
Net Income After Taxes | -67.414 | -57.419 | -128.784 | -47.568 | -57.584 |
Net Income Before Extra. Items | -67.414 | -57.419 | -128.784 | -47.568 | -57.584 |
Net Income | -67.414 | -57.419 | -128.784 | -47.568 | -57.584 |
Income Available to Common Excl. Extra. Items | -67.414 | -57.419 | -128.784 | -47.568 | -57.584 |
Income Available to Common Incl. Extra. Items | -67.414 | -57.419 | -128.784 | -47.568 | -57.584 |
Diluted Net Income | -67.414 | -57.419 | -128.784 | -47.568 | -57.584 |
Diluted Weighted Average Shares | 223.883 | 212.663 | 216.34 | 189.565 | 187.052 |
Diluted EPS Excluding Extraordinary Items | -0.30111 | -0.27 | -0.59529 | -0.25093 | -0.30785 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.30231 | -0.27095 | -0.59547 | -0.25187 | -0.30797 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 584.029 | 940.019 | 1389.85 | 57.175 | 73.07 |
Cash and Short Term Investments | 497.733 | 813.4 | 1323.02 | 31.114 | 60.404 |
Cash & Equivalents | 495.797 | 811.464 | 1322.59 | 30.684 | 21.38 |
Short Term Investments | 1.936 | 1.936 | 0.43 | 0.43 | 39.024 |
Total Receivables, Net | 11.553 | 21.216 | 4.011 | 18.714 | 8.848 |
Accounts Receivable - Trade, Net | 9.002 | 18.504 | 1.822 | 17.153 | 6.858 |
Total Inventory | 23.989 | 56.159 | 14.531 | 6.197 | 2.951 |
Prepaid Expenses | 4.507 | 5.724 | 40.054 | 1.15 | 0.421 |
Other Current Assets, Total | 46.247 | 43.52 | 8.235 | 0.446 | |
Total Assets | 860.472 | 1158.24 | 1511.36 | 130.62 | 125.659 |
Property/Plant/Equipment, Total - Net | 241.702 | 200.393 | 100.589 | 61.686 | 40.472 |
Property/Plant/Equipment, Total - Gross | 271.27 | 247.412 | 145.054 | 84.931 | 58.497 |
Accumulated Depreciation, Total | -29.568 | -47.019 | -44.466 | -23.245 | -18.025 |
Intangibles, Net | 19.315 | 13.238 | 14.146 | 5.698 | 6.213 |
Note Receivable - Long Term | 0.302 | 1.08 | 1.034 | 0.966 | 0.749 |
Other Long Term Assets, Total | 2.661 | 3.512 | 5.733 | 5.095 | 5.155 |
Total Current Liabilities | 156.225 | 357.734 | 247.622 | 28.086 | 28.13 |
Accounts Payable | 73.463 | 127.703 | 21.685 | 5.331 | 9.029 |
Accrued Expenses | 39.289 | 46.802 | 50.022 | 12.068 | 12.258 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.98 | 3.469 | 3.234 | 2.004 | 0.077 |
Other Current Liabilities, Total | 38.493 | 179.76 | 172.681 | 8.683 | 6.766 |
Total Liabilities | 327.219 | 469.766 | 800.009 | 173.422 | 93.576 |
Total Long Term Debt | 37.106 | 25.423 | 52.042 | 77.144 | 0 |
Long Term Debt | 0 | 25.189 | 65.018 | 0 | |
Capital Lease Obligations | 37.106 | 25.423 | 26.853 | 12.126 | 0 |
Deferred Income Tax | 0 | 1.623 | 0 | ||
Other Liabilities, Total | 133.888 | 86.609 | 500.345 | 66.569 | 65.446 |
Total Equity | 533.253 | 688.476 | 711.347 | -42.802 | 32.083 |
Common Stock | 23.4 | 22.454 | 21.655 | 0.727 | 0.727 |
Retained Earnings (Accumulated Deficit) | 511.473 | 671.873 | 689.635 | -43.551 | 31.366 |
Other Equity, Total | -0.139 | -0.034 | 0.057 | 0.022 | -0.01 |
Total Liabilities & Shareholders’ Equity | 860.472 | 1158.24 | 1511.36 | 130.62 | 125.659 |
Total Common Shares Outstanding | 194.958 | 187.121 | 180.461 | 176.46 | 176.46 |
Treasury Stock - Common | -1.481 | -5.817 | |||
Goodwill, Net | 12.463 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 536.833 | 603.21 | 686.916 | 584.029 | 622.282 |
Cash and Short Term Investments | 467.6 | 543.279 | 620.588 | 500.284 | 543.464 |
Cash & Equivalents | 464.145 | 537.925 | 617.519 | 495.797 | 540.865 |
Short Term Investments | 3.455 | 5.354 | 3.069 | 4.487 | 2.599 |
Total Receivables, Net | 10.594 | 6.562 | 5.843 | 9.002 | 6.17 |
Accounts Receivable - Trade, Net | 10.594 | 6.562 | 5.843 | 9.002 | 6.17 |
Total Inventory | 23.3 | 22.194 | 24.678 | 23.989 | 7.868 |
Prepaid Expenses | 25.453 | 21.221 | 25.597 | 40.287 | 60.952 |
Other Current Assets, Total | 9.886 | 9.954 | 10.21 | 10.467 | 3.828 |
Total Assets | 842.566 | 899.48 | 973.672 | 860.472 | 910.512 |
Property/Plant/Equipment, Total - Net | 272.217 | 261.57 | 253.163 | 241.702 | 251.461 |
Intangibles, Net | 30.469 | 31.7 | 30.6 | 31.778 | 33.775 |
Other Long Term Assets, Total | 3.047 | 3 | 2.993 | 2.963 | 2.994 |
Total Current Liabilities | 150.679 | 156.276 | 90.298 | 156.225 | 172.352 |
Payable/Accrued | 12.57 | 13.419 | 14.973 | 73.463 | 52.608 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 5.534 | 5.205 | 5.058 | 4.98 | 4.652 |
Other Current Liabilities, Total | 132.575 | 137.652 | 70.267 | 77.782 | 115.092 |
Total Liabilities | 240.301 | 250.433 | 260.273 | 327.219 | 285.524 |
Total Long Term Debt | 36.58 | 35.276 | 36.087 | 37.106 | 36.609 |
Long Term Debt | |||||
Capital Lease Obligations | 36.58 | 35.276 | 36.087 | 37.106 | 36.609 |
Other Liabilities, Total | 53.042 | 58.881 | 133.888 | 133.888 | 76.563 |
Total Equity | 602.265 | 649.047 | 713.399 | 533.253 | 624.988 |
Common Stock | 26.871 | 26.866 | 26.862 | 23.4 | 22.834 |
Retained Earnings (Accumulated Deficit) | 575.547 | 622.304 | 687.001 | 511.473 | 604.286 |
Treasury Stock - Common | 0 | 0 | -0.344 | -1.481 | -1.734 |
Other Equity, Total | -0.153 | -0.123 | -0.12 | -0.139 | -0.398 |
Total Liabilities & Shareholders’ Equity | 842.566 | 899.48 | 973.672 | 860.472 | 910.512 |
Total Common Shares Outstanding | 223.924 | 223.873 | 223.819 | 194.958 | 190.244 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -249.155 | -412.498 | -129.848 | -100.125 | -71.131 |
Cash From Operating Activities | -286.177 | -733.128 | 522.403 | -86.963 | -74.11 |
Cash From Operating Activities | 23.741 | 15.674 | 10.671 | 7.164 | 3.781 |
Non-Cash Items | 67.744 | -350.082 | 40.194 | 20.432 | -5.889 |
Cash Taxes Paid | 0.128 | 0.502 | 0.093 | 0.345 | 0.026 |
Changes in Working Capital | -128.511 | 15.361 | 602.482 | -14.434 | -0.871 |
Cash From Investing Activities | -93.499 | -127.901 | -45.274 | 28.181 | -4.264 |
Capital Expenditures | -93.222 | -127.901 | -47.352 | -12.224 | -14.723 |
Other Investing Cash Flow Items, Total | -0.277 | 0 | 2.078 | 40.405 | 10.459 |
Cash From Financing Activities | 63.173 | 344.964 | 819.833 | 67.979 | -0.112 |
Issuance (Retirement) of Debt, Net | -4.221 | -28.183 | -47.884 | 67.979 | -0.112 |
Foreign Exchange Effects | 0.836 | 4.936 | -5.053 | 0.107 | 0.213 |
Net Change in Cash | -315.667 | -511.129 | 1291.91 | 9.304 | -78.273 |
Cash Interest Paid | 4.606 | 9.785 | 8.694 | 0.824 | |
Deferred Taxes | 0.004 | -1.583 | -1.096 | ||
Issuance (Retirement) of Stock, Net | 0.91 | 373.147 | 867.717 | ||
Financing Cash Flow Items | 66.484 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -57.418 | -249.155 | -120.405 | -72.759 | -15.189 |
Cash From Operating Activities | -99.586 | -286.177 | -237.091 | -201.175 | -136.511 |
Cash From Operating Activities | 5.853 | 23.741 | 23.349 | 16.651 | 9.077 |
Deferred Taxes | 0.002 | 0.004 | 0.049 | -0.01 | |
Non-Cash Items | -0.347 | 67.744 | -14.466 | -20.765 | -13.72 |
Cash Taxes Paid | 0.004 | 0.128 | 0.152 | 0.126 | |
Cash Interest Paid | 0.633 | 4.606 | 3.326 | 2.608 | 1.33 |
Changes in Working Capital | -47.676 | -128.511 | -125.618 | -124.292 | -116.679 |
Cash From Investing Activities | -13.162 | -93.499 | -72.559 | -44.715 | -17.185 |
Capital Expenditures | -13.162 | -93.222 | -72.559 | -44.715 | -17.185 |
Other Investing Cash Flow Items, Total | -0.277 | ||||
Cash From Financing Activities | 234.709 | 63.173 | 29.873 | 3.409 | -0.46 |
Issuance (Retirement) of Stock, Net | 235.969 | 0.91 | 0.635 | 0.631 | 0.44 |
Issuance (Retirement) of Debt, Net | -1.26 | -4.221 | -3.087 | -1.943 | -0.9 |
Foreign Exchange Effects | -0.239 | 0.836 | 9.178 | 4.583 | 0.895 |
Net Change in Cash | 121.722 | -315.667 | -270.599 | -237.898 | -153.261 |
Financing Cash Flow Items | 66.484 | 32.325 | 4.721 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
CureVac N.V. Company profile
CureVac N.V. (CVAC) is a global clinical-stage biopharmaceutical company that develops medicines based on messenger ribonucleic acid (mRNA).
The company was founded in 2000 and is headquartered in Tübingen, Germany. It is listed on the NASDAQ stock exchange in August 2020 under the ticker symbol ‘CVAC.’
CureVac’s product portfolio is focused on oncology, infectious diseases and protein therapy. According to the company, its lead clinical programmes are CV8102 for the treatment of four types of solid tumours and CV7202 for potential vaccination against rabies.
The company has partnered with UK-based pharmaceutical firm GlaxoSmithKline (GSK) to develop second-generation mRNA vaccines for Covid-19 with the potential to address multiple emerging variants with one vaccine. CureVac’s first generation mRNA Covid-19 vaccine candidate CVnCoV is also under development.
CureVac N.V. and GSK are also developing an influenza vaccine together. Other vaccines currently under development are for yellow fever, respirational syncytial virus, rota, malaria and universal influenza.
According to the company’s prospectus, the company originally existed as CureVac AG. A Dutch private holding company CureVac B.V. was incorporated and CureVac AG was made a unit of the holding company. CureVac B.V. was then converted to a Dutch public company named CureVac N.V. The current chief executive of the company is Franz-Werner Haas.
According to the company’s price history, CVAC stock price hit an all-time high of $151.8 per share in December 2020. The company has not distributed dividends since going public.
You can follow the ups and downs of the CVAC share value at Capital.com. Always stay on top of the latest price developments with our live CVAC stock chart.
Industry: | Biotechnology & Medical Research (NEC) |
Friedrich-Miescher-Str. 15
TUEBINGEN
BADEN-WUERTTEMBERG 72076
DE
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com